DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/44f15d/competitor_analysi) has announced the addition of the "Competitor Analysis: G-CSF and GM-CSF" report to their offering.
The present Competitive Intelligence Report about G-CSF & GM-CSF products in the pipeline and off-patent products provides a competitor evaluation in the field of G-CSF & GM-CSF branded products in regulated markets and products in non-regulated markets, biosimilars (biogenerics, follow-on biologics) and next generation, longer acting products or new uses of G-CSF as of January 2011. Purchase of the downloadable PDF report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of currently marketed branded and non-branded G-CSF and GM-CSF products in regulated and non-regulated markets for treatment of chemotherapy-induced neutropenia. The report includes the market size of branded G-CSF products in 2009. It lists the most advanced biosimilars of G-CSF and pegylated G-CSF and of GM-CSF. It describes the companies with G-CSF and GM-CSF products and of pegylated versions in non-regulated markets. In addition, the report lists company-specific R&D pipelines of G-CSF/GM-CSF products and projects. Competitor projects are listed in a tabular format providing Information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Territory,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
Key Topics Covered:
- 1st Generation branded G-CSF products in regulated markets
- Biosimilar 1st generation G-CSF products in regulated markets
- Next generation G-CSF products and uses in regulated markets
- Biosimilar next generation G-CSF products and uses in regulated markets
- 1st generation G-CSF products in non-regulated markets
- Next generation G-CSF products in non-regulated markets
- 1st and next generation GM-CSF products in regulated markets
- 1st and next generation GM-CSF products in non-regulated markets
- About La Merie
48 Companies Mentioned, Some Include:
Corporate G-CSF & GM-CSF R&D Pipelines
- Acorn Biomedical
- Amgen
- Apricus Biosciences
- Beijing SL
- Pharmaceutical Co
- Bolder BioTechnology
- Cangene
- Dong-A Pharmaceutical
- Fuji Pharma
- Genzyme
- Green Cross
- Hospira
- Intas Biopharmaceuticals
- Kyowa Hakko Kirin Pharma
- NCPC GeneTech Biotechnology Development
- Octapharma
- Phage Pharmaceuticals
- PharmaEssentia
- Recoly
- Reliance GeneMedix
- Reliance Life Sciences
- Serum Institute of India
- Shandong GeneLeuk Biopharma
- USV Ltd.
- Xiamen Amoytop Biotech
- Zenotech Laboratories
- Zydus Cadila
For more information visit http://www.researchandmarkets.com/research/44f15d/competitor_analysi